Despite the evidence, visual estimation continues to dominate the decision on intermediate lesions

Original title: Revascularization Decisions in Patients With Stable Angina and Intermediate Lesions. Results of the International Survey on Interventional Strategy. Reference: Gabor G. Toth et al. CircCardiovascInterv. 2014. Epubahead of print.

 

Measurement of fractional flow reserve (FFR) is recommended by the guidelines and supported by evidence in intermediate lesions when not any proof of ischemia is available by noninvasive testing. The International Survey on Interventional Strategy evaluated the preferred approach of 495 experienced Interventional Cardiologists from several centers around the world who gave their opinion on a total of 4421 injuries. In the case of intermediate lesions by visual estimation they had the choice to define the strategy using the following; quantitative angiography, intravascular ultrasound (IVUS), optical coherence tomography (OCT) and fractional flow reserve (FFR). In 3158 lesions (71%), the decision was made relying merely on the angiographic appearance that in other hand was discordant in 47% with the measurement of FFR. 

FFR or other imaging modalities were required at 21% and 8% respectively. When comparing the 4 groups of participants according to their experience in FFR, it was observed that decisions based exclusively on angiography were less frequent as the FFR experience increased (77% versus 72% versus 69% versus 67%, respectively; p <0.001). As a result, the FFR was used more frequently (14% versus 19% versus 24% versus 28%, respectively; p <0.001) and the number of discordant decisions decreased (51% versus 49% versus 47% versus 43%, respectively; p <0.022).

Conclusion

These findings confirm that the visual estimation continues ruling the decision making in intermediate lesions indicating a worrying disengage between evidence, guidelines, and daily practice.

Editorial comment

Cost seems the simplest explanation that arises from the difference of what should be done and what is done in practice. Yet, all these interventionists had the possibility to select any of the methods available and they did not because they simply relied on angiography.

SOLACI

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....